The ODD strengthens REYOBIQ's development trajectory and commercial prospects in a high-unmet-need pediatric CNS cancer market. Traders should monitor upcoming clinical trial data readouts, particularly from ReSPECT-PBC, as next catalysts.
Price Chart
Executive Summary
Plus Therapeutics announced that its drug REYOBIQ received Orphan Drug Designation (ODD) from the FDA for the treatment of pediatric malignant gliomas, including pediatric ependymoma. This designation provides potential benefits such as seven years of market exclusivity upon approval, tax credits, and regulatory fee exemptions.
Key Facts
- REYOBIQ (rhenium Re186 obisbemeda) granted Orphan Drug Designation by the FDA for pediatric malignant gliomas
- Indication includes pediatric ependymoma, broader than originally requested
- Orphan Drug Designation provides 7 years of market exclusivity upon approval, tax credits for clinical trial expenses, and regulatory fee exemptions
- REYOBIQ is being evaluated in multiple clinical trials including ReSPECT-GBM, ReSPECT-LM, and ReSPECT-PBC
- Company has received FDA clearance for IND application in pediatric high-grade glioma and ependymoma
Financial Impact
No immediate financial impact reported, but ODD enhances commercial potential through future market exclusivity and development incentives
Risk Factors
- Clinical trial failure risk remains as REYOBIQ is still investigational
- Small market size typical of orphan indications may limit peak revenue potential
- Company's market cap ($20M) suggests high execution risk and potential funding needs
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-146335 |
| Document: pstv-ex99_1.htm | 0001193125-26-146335 |
| Document: 0001193125-26-146335-index-headers.html | 0001193125-26-146335 |
| Document: 0001193125-26-146335-index.html | 0001193125-26-146335 |
| Document: 0001193125-26-146335.txt | 0001193125-26-146335 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Jul 21, 2026 13w ago | Press Release | $3.92 | awaiting T+20 | — | — |
Jun 30, 2026 16w ago | Press Release | $4.37 $3.73 | ▼ −14.65% | ▼ −13.62% | — |
Jun 8, 2026 20w ago | EFFECT | $5.53 $4.05 | ▲ +26.76% | ▲ +28.39% | — |
Jun 5, 2026 20w ago | S-3/A | $5.41 $4.05 | ▼ −25.14% | ▼ −27.00% | — |
May 19, 2026 22w ago | Press Release | $5.83 $4.31 | ▼ −26.07% | ▼ −27.06% | — |
May 15, 2026 23w ago | Press Release | $5.84 $4.57 | ▲ +21.75% | ▲ +23.33% | — |
May 8, 2026 24w ago | Press Release | $6.12 $5.41 | ▼ −11.60% | ▼ −11.62% | — |
Apr 28, 2026 25w ago | Press Release | $5.95 $6.60 | ▲ +10.92% | ▲ +5.46% | — |
Apr 21, 2026 26w ago | 8-K | $7.14 $5.84 | ▼ −18.21% | ▼ −23.12% | — |
Apr 9, 2026 28w ago | 8-K | $3.92 $6.00 | ▲ +53.06% | ▲ +45.49% | — |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers